• Shandong Xinhua Pharmaceutical won China NMPA marketing authorization for sacubitril valsartan sodium tablets, 50 mg (24 mg/26 mg).
• Approval covers domestic production for adult chronic heart failure with reduced ejection fraction; product can replace ACEI or ARB regimens.
• China public medical-institution sales for sacubitril valsartan tablets totaled about RMB 7.8 billion in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261008-12366973), on October 08, 2026, and is solely responsible for the information contained therein.